Key facts
- Notable investors include Addor Capital, Cowin Capital, Hefei Hi-Tech VC, Shenzhen Yifeng Investment Management Enterprise, CAS Investment Management — 20 tracked in total.
- Status: Privately Held (backing).
Investors
20+- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Inno Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Inno Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inno Medicine
Developer of cardiovascular medical technology intended for the precise treatment of atherosclerosis. The company offers innovative medicines use nano-delivery platform technology to deliver contrast agents or anti-atherosclerotic drugs to atherosclerotic plaques for early identification and treatment of atherosclerosis-related diseases, enabling patients to use medications as an alternative to coronary stenting and surgical bypass surgery to some extent.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Employees
- 11
- Website
- innovmedicine.com/
- Ownership
- Privately Held (backing)
Inno Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inno Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inno Medicine in its N-PORT filings yet. We sweep new filings monthly.